Vadadustat is an investigational oral hypoxia-inducible factor prolyl
hydroxylase inhibitor, or HIF-PHI, in global Phase 3 development for the treatment of anemia due to CKD in dialysis dependent, or DD,-CKD patients and non-dialysis dependent, or NDD,-CKD patients.
Roxadustat is a hypoxia-inducible factor prolyl
hydroxylase inhibitor that promotes erythropoiesis by increasing endogenous production of erythropoietin and improving iron regulation, and overcoming the negative impact of inflammation on haemoglobin synthesis and red blood cell production by downregulating hepcidin.
Tom founded FibroGen in 1993 when he assembled the global scientific leaders in both collagen synthesis and the molecular and cellular mechanisms of prolyl
United Kingdom-based GlaxoSmithKline has submitted a Japanese New Drug Application (JNDA) to the Ministry of Health, Labour and Welfare, seeking marketing approval for Daprodustat, an oral hypoxia-inducible factor prolyl
hydroxylase inhibitor, it was reported yesterday.
Daprodustat is a hypoxia-inducible factor prolyl
hydroxylase inhibitor, a new class of drugs which encourage the bone marrow to increase red blood cell production.
FitzGerald, Peptide identification in a porcine gelatin prolyl
endoproteinase hydrolysate with angiotensin converting enzyme (ACE) inhibitory and hypotensive activity, J.
Tenders are invited for For supply and installation of equipments in the dbt funded project entitled prolyl
hydroxylase mediated stabilization of hypoxia inducible factor one alfa regulate glycolysis and fatty acid
AstraZeneca Plc (LON:AZN), a science-led biopharmaceutical company, announced on Tuesday that its partner FibroGen (China) Medical Technology Development Co Ltd (FibroGen China) has now received formal marketing authorisation from the National Medical Products Administration (NMPA) for roxadustat, a first-in-class hypoxia-inducible factor prolyl
hydroxylase inhibitor (HIF-PHI) and new oral treatment for patients with anaemia caused by chronic kidney disease (CKD) that are on dialysis.
Akebia's vadadustat is an investigational Phase 3 oral hypoxia-inducible factor prolyl
hydroxylase inhibitor (HIF-PHI) with the potential to advance the treatment of patients with anemia due to CKD, many of whom are currently receiving injectable erythropoietin-stimulating agents.
It reduced pulmonary inflammation by decreasing prolyl
endopeptidase activity and acetyl-proline-glycine-proline. In a therapeutic protocol, the influence of using PDE-4 inhibitors to reduce lung fibrosis was almost same to nintedanib and pirfenidone.
Another important facet of IDH mutations is 2-HG-mediated modulation of prolyl
hydroxylases, in particular the [alpha]-KG-dependent prolyl
Under normoxic conditions, the HIF-[alpha] is hydroxylated by specific prolyl
hydroxylase (PHD) and is rapidly degraded via the ubiquitin-proteasomal system.